BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7646540)

  • 21. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines.
    Drake JC; Allegra CJ; Moran RG; Johnston PG
    Biochem Pharmacol; 1996 May; 51(10):1349-55. PubMed ID: 8787551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
    van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ
    Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay.
    Horowitz RW; Zhang H; Schwartz EL; Ladner RD; Wadler S
    Biochem Pharmacol; 1997 Sep; 54(5):635-8. PubMed ID: 9337081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
    Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
    Zhao R; Hanscom M; Chattopadhyay S; Goldman ID
    Cancer Res; 2004 May; 64(9):3313-9. PubMed ID: 15126375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex).
    Yin MB; Voigt W; Panadero A; Vanhoefer U; Frank C; Pajovic S; Azizkhan J; Rustum YM
    Mol Pharmacol; 1997 Apr; 51(4):630-6. PubMed ID: 9106628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
    Li WW; Tong WP; Bertino JR
    Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.
    Ward WH; Kimbell R; Jackman AL
    Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular, biochemical, and cellular pharmacology of pemetrexed.
    Goldman ID; Zhao R
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
    Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
    Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.
    Pressacco J; Mitrovski B; Erlichman C; Hedley DW
    Cancer Res; 1995 Apr; 55(7):1505-8. PubMed ID: 7882359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Int J Oncol; 2003 Aug; 23(2):401-9. PubMed ID: 12851689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
    Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
    McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR
    Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine.
    Zhang ZG; Malmberg M; Yin MB; Slocum HK; Rustum YM
    Biochem Pharmacol; 1993 Mar; 45(5):1157-64. PubMed ID: 8461045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.